432 related articles for article (PubMed ID: 29190166)
1. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery.
Cole BK; Feaver RE; Wamhoff BR; Dash A
Expert Opin Drug Discov; 2018 Feb; 13(2):193-205. PubMed ID: 29190166
[TBL] [Abstract][Full Text] [Related]
2. Mouse models of nonalcoholic steatohepatitis in preclinical drug development.
Hansen HH; Feigh M; Veidal SS; Rigbolt KT; Vrang N; Fosgerau K
Drug Discov Today; 2017 Nov; 22(11):1707-1718. PubMed ID: 28687459
[TBL] [Abstract][Full Text] [Related]
3. Preclinical models of non-alcoholic fatty liver disease.
Santhekadur PK; Kumar DP; Sanyal AJ
J Hepatol; 2018 Feb; 68(2):230-237. PubMed ID: 29128391
[TBL] [Abstract][Full Text] [Related]
4. How effective are nonalcoholic fatty liver disease models for drug discovery?
Hundertmark J; Tacke F
Expert Opin Drug Discov; 2020 Nov; 15(11):1237-1240. PubMed ID: 32524859
[TBL] [Abstract][Full Text] [Related]
5. Promising therapies for treatment of nonalcoholic steatohepatitis.
Noureddin M; Zhang A; Loomba R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
[TBL] [Abstract][Full Text] [Related]
6. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
7. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
Tacke F
Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic Steatohepatitis (NASH) Drug Discovery - Building a Consensus on ADME Screening Tools and Clinical Pharmacology Strategies to Aid Candidate Development.
Dash RP; Babu RJ; Srinivas NR
J Pharm Pharm Sci; 2018; 21(1):481-495. PubMed ID: 30472977
[TBL] [Abstract][Full Text] [Related]
9. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
10. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
11. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis.
Oseini AM; Cole BK; Issa D; Feaver RE; Sanyal AJ
Hepatol Int; 2018 Jan; 12(1):6-16. PubMed ID: 29299759
[TBL] [Abstract][Full Text] [Related]
12. Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis.
Thomsen KL; De Chiara F; Rombouts K; Vilstrup H; Andreola F; Mookerjee RP; Jalan R
Med Hypotheses; 2018 Apr; 113():91-97. PubMed ID: 29523305
[TBL] [Abstract][Full Text] [Related]
13. Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease.
Dietrich CG; Rau M; Jahn D; Geier A
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):625-640. PubMed ID: 28359183
[TBL] [Abstract][Full Text] [Related]
14. Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease.
Goossens N; Jornayvaz FR
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28956824
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
Cernea S; Cahn A; Raz I
Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
[TBL] [Abstract][Full Text] [Related]
16. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
[TBL] [Abstract][Full Text] [Related]
17. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
18. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.
Ogawa Y; Yoneda M; Kobayashi T; Honda Y; Kessoku T; Imajo K; Saito S; Nakajima A
Expert Opin Pharmacother; 2019 Jan; 20(1):69-82. PubMed ID: 30411635
[TBL] [Abstract][Full Text] [Related]
19. Future trends in the treatment of non-alcoholic steatohepatitis.
Fiorucci S; Biagioli M; Distrutti E
Pharmacol Res; 2018 Aug; 134():289-298. PubMed ID: 30021122
[TBL] [Abstract][Full Text] [Related]
20. Customized liver organoids as an advanced
Han DW; Xu K; Jin ZL; Xu YN; Li YH; Wang L; Cao Q; Kim KP; Ryu D; Hong K; Kim NH
Int J Biol Sci; 2023; 19(11):3595-3613. PubMed ID: 37497008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
